However, a report conducted by Rulifson et al. [46] provided contradictory findings that overexpressed SFRP5 actually reduced glucose intolerance and produced hyperglycemia, while the treatment of monoclonal antibody against SFRP5 intensified glucose metabolism. Here, SFRP5 is linked to Hyperglycemia.